重组百日咳疫苗加强免疫5年后的百日咳免疫力 - Suppr

Suppr

超能文献

Pertussis Immunity 5 Years After Booster Vaccination With Recombinant Pertussis Vaccines.

作者信息

Pitisuttithum Punnee, Sirivichayakul Chukiat, Dhitavat Jittima, Pitisuthitham Arom, Mansouri Souad, Pham Hong Thai

机构信息

Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, Ratchathewi, Bangkok, Thailand.

BioNet-Asia Co Ltd, Bangjak, Prakanong, Bangkok, Thailand.

出版信息

JAMA Netw Open. 2024 Dec 2;7(12):e2449182. doi: 10.1001/jamanetworkopen.2024.49182.

DOI:10.1001/jamanetworkopen.2024.49182

PMID:39636641

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11621984/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/873d/11621984/89c71948377f/jamanetwopen-e2449182-g001.jpg

相似文献

Pertussis Immunity 5 Years After Booster Vaccination With Recombinant Pertussis Vaccines.重组百日咳疫苗加强免疫5年后的百日咳免疫力

JAMA Netw Open. 2024 Dec 2;7(12):e2449182. doi: 10.1001/jamanetworkopen.2024.49182.

Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aP or combined TdaP vaccines.青少年接种重组无细胞百日咳单价aP疫苗或联合Tdap疫苗加强免疫2年和3年后的抗体持久性

EClinicalMedicine. 2021 Jun 23;37:100976. doi: 10.1016/j.eclinm.2021.100976. eCollection 2021 Jul.

A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults.一项在成人中研究新型无细胞百日咳（aP）和减少破伤风-白喉-无细胞百日咳（TdaP）加强疫苗的 I 期、随机、对照、剂量范围研究。

Hum Vaccin Immunother. 2018 Jan 2;14(1):45-58. doi: 10.1080/21645515.2017.1385686. Epub 2017 Nov 27.

Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.十年期联合低抗原含量白喉-破伤风-无细胞百日咳和灭活脊髓灰质炎病毒加强疫苗（dTpa-IPV）在健康成年人中的免疫原性和反应原性。

Vaccine. 2015 May 21;33(22):2594-601. doi: 10.1016/j.vaccine.2015.03.104. Epub 2015 Apr 14.

Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.吸附无细胞百白破灭活、全细胞百日咳和破伤风联合疫苗（Boostrix®）：作为单剂加强免疫的特性和用途介绍。

Drugs. 2012 Sep 10;72(13):1765-91. doi: 10.2165/11209630-000000000-00000.

Effectiveness of routine and booster pertussis vaccination in children and adolescents, federal state of Brandenburg, Germany, 2002-2012.2002 - 2012年德国勃兰登堡州儿童和青少年常规及加强百日咳疫苗接种的有效性

Pediatr Infect Dis J. 2015 May;34(5):513-9. doi: 10.1097/INF.0000000000000654.

A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women.一项在孕妇中使用含基因失活百日咳毒素的重组百日咳加强疫苗的 2 期随机对照剂量范围试验。

Vaccine. 2023 Jul 12;41(31):4541-4553. doi: 10.1016/j.vaccine.2023.06.001. Epub 2023 Jun 15.

A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.一种基因失活的两组分无细胞百日咳疫苗，单独或与破伤风和低剂量白喉疫苗联合使用，在青少年中的 2/3 期、随机对照非劣效性试验。

Lancet Infect Dis. 2018 Jan;18(1):58-67. doi: 10.1016/S1473-3099(17)30612-6. Epub 2017 Oct 20.

Infant Responses to Primary Immunization Following Vaccination in Pregnancy With Varying Doses of Recombinant Acellular Pertussis Vaccine Alone or Combined With Tetanus-Diphtheria.孕期接种不同剂量重组无细胞百日咳疫苗单独或联合破伤风-白喉疫苗后婴儿对初次免疫的反应。

Pediatr Infect Dis J. 2025 Feb 1;44(2S):S56-S60. doi: 10.1097/INF.0000000000004609. Epub 2025 Feb 14.

Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trial.青少年接种单价和结合无细胞百日咳疫苗（含基因失活百日咳毒素）后的抗体持久性：一项 2/3 期随机、对照、非劣效性试验。

Lancet Infect Dis. 2018 Nov;18(11):1260-1268. doi: 10.1016/S1473-3099(18)30375-X. Epub 2018 Sep 25.

引用本文的文献

Avidity of pertussis toxin antibodies following vaccination with genetically versus chemically detoxified pertussis toxin-containing vaccines during pregnancy.孕期接种含基因解毒与化学解毒百日咳毒素疫苗后百日咳毒素抗体的亲和力

Front Immunol. 2025 May 22;16:1569151. doi: 10.3389/fimmu.2025.1569151. eCollection 2025.

本文引用的文献

EClinicalMedicine. 2021 Jun 23;37:100976. doi: 10.1016/j.eclinm.2021.100976. eCollection 2021 Jul.

Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines.百日咳预防：卷土重来的原因，以及当前无细胞百日咳疫苗的差异。

Front Immunol. 2019 Jul 3;10:1344. doi: 10.3389/fimmu.2019.01344. eCollection 2019.

Lancet Infect Dis. 2018 Jan;18(1):58-67. doi: 10.1016/S1473-3099(17)30612-6. Epub 2017 Oct 20.

What Is Wrong with Pertussis Vaccine Immunity? Inducing and Recalling Vaccine-Specific Immunity.百日咳疫苗免疫有何问题？诱导和回忆疫苗特异性免疫。

Cold Spring Harb Perspect Biol. 2017 Dec 1;9(12):a029629. doi: 10.1101/cshperspect.a029629.

Waning Tdap Effectiveness in Adolescents.青少年 Tdap 疫苗效力下降。

Pediatrics. 2016 Mar;137(3):e20153326. doi: 10.1542/peds.2015-3326. Epub 2016 Feb 5.

The vaccine containing recombinant pertussis toxin induces early and long-lasting protection.含有重组百日咳毒素的疫苗可诱导早期且持久的保护作用。

Biologicals. 1999 Jun;27(2):99-102. doi: 10.1006/biol.1999.0189.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验